These so - called «living drugs» — injected T cells genetically modified to better recognize and
kill tumor cells through a perpetual process of cell renewal and expansion — are revolutionizing cancer treatment, with the first two FDA approvals of such gene - altering therapies occurring in just the last two months.
Not exact matches
Giving the mice antibiotics helped gemcitabine
kill tumor cells, increasing the number of
tumor cells going
through a type of
cell death called apoptosis from about 15 percent to 60 percent or more.
Over the past two years, investigators from the Perelman School of Medicine at the University of Pennsylvania have reported results from a human trial in GBM using chimeric antigen receptor (CAR) T
cell therapy,
through which patients» own T
cells were engineered to track down and
kill cancer
cells that express a
tumor - specific protein known as EGFRvIII.
«Most chemotherapies
kill cancer
cells through apoptosis, and the cancer
cells that escape apoptosis are the root cause of chemotherapy resistance and
tumor progression,» said Chi.
Both strains spread
through the
tumors, infecting and
killing the cancer stem
cells while largely avoiding other
tumor cells.
The result — still a preliminary finding — illustrates the potential for improved cancer treatment
through saddling a cancer -
killing virus on the back of a
tumor - targeting immune
cell.
Drug from Mediterranean Weed
Kills Tumor Cells Scientists at the Johns Hopkins Kimmel Cancer Center, working with Danish researchers, have developed a novel anticancer drug designed to travel — undetected by normal cells — through the bloodstream until activated by specific cancer prot
Cells Scientists at the Johns Hopkins Kimmel Cancer Center, working with Danish researchers, have developed a novel anticancer drug designed to travel — undetected by normal
cells — through the bloodstream until activated by specific cancer prot
cells —
through the bloodstream until activated by specific cancer proteins.
While this virus was hypothesized to
kill osteosarcoma
cells through its replication, we have recently recognized the possibility that the virus stimulates an immune response to
tumor, in addition to itself.
M032
kills tumor cells directly
through oncolytic replication and then proceeds to infect
tumor cells in proximity, continuing the process of
tumor destruction.